The outcomes of this project confirmed the therapeutic potential of siRNA in combination with designer nanoparticles from lipopolymers as a delivery system. The new therapy we proposed, based on molecular targeting of cancer driving STAT5 gene, has shown promising results in cell models of acute lymphocytic leukemia (ALL). We see similarly successful results in a subset of patient-derived ALL samples as well, but the response was not uniformly positive in all patient samples.

University of Alberta
116 St & 85 Ave
Edmonton, AB T6G 2R3
Canada